Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

This study is using stored blood samples from people with metastatic colorectal cancer to see whether specific chemical tags on tumor DNA in the blood (5mC and 5hmC markers) can predict how well a patient responds to targeted therapies — either drugs that block a protein called EGFR (cetuximab or panitumumab) or drugs that block blood vessel growth (bevacizumab). **You may be eligible if...** - You have confirmed metastatic colorectal adenocarcinoma - You received EGFR-targeted therapy (cetuximab or panitumumab) or VEGF-targeted therapy (bevacizumab) - Pre-treatment plasma samples for DNA analysis are available - Your RAS and BRAF mutation status is documented - Your treatment response was formally assessed on scans **You may NOT be eligible if...** - Your stored blood samples are of low quality or insufficient quantity - Your cancer was not an adenocarcinoma histology - You have another active concurrent cancer - You have an active autoimmune or inflammatory disease that could distort the DNA methylation results being studied Talk to your doctor to see if this trial is right for you.